- Karyopharm Therapeutics (NASDAQ:KPTI) announces positive results from a Phase 3 clinical trial, SEAL, evaluating Xpovio (selinexor) in patients with advanced unresectable dedifferentiated liposarcoma, a high-grade subtype of the rare form of soft tissue cancer that begins in fat cells.
- The study met the primary endpoint of progression-free survival (PFS) with 30% less risk of cancer progression or death (hazard ratio = 0.70).
- No new safety signals were observed.
- Detailed results will be virtually presented at the Connective Tissue Oncology Society Annual Meeting on Friday, November 20.
- The FDA approved Xpovio in July 2019 for multiple myeloma and in June of this year for diffuse large B-cell lymphoma.
https://seekingalpha.com/news/3630016-karyopharms-selinexor-successful-in-late-stage-study-in-rare-soft-tissue-cancer
Monday, November 2, 2020
Karyopharm's selinexor successful in late-stage study in rare soft tissue cancer
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.